Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 in moderate to severe obesity
NCT07000955Phase 2Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of mazdutide in obesity, sponsored by Innovent Biologics. Started Jun 2025; status: active, not recruiting.
02
Drugs
mazdutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07000955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000955.